The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Connective Tissue Disease-Associated Interstitial Lung Disease

결체조직질환을 동반한 간질성 폐렴

  • Chung, Man Pyo (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 정만표 (성균관대학교 의과대학 내과학교실)
  • Published : 2013.04.01
⟨ Previous Next ⟩

Abstract

Interstitial lung disease (ILD) is the most common pulmonary manifestation of connective tissue disease (CTD). It may develop in the patients with preexisting connective tissue diseases or may be the initial lone manifestation of an underlying CTD. Since ILD causes a potentially substantial morbidity and mortality in the patients with CTD, close collaboration among pulmonologists, rheumatologists, radiologists and pathologists is very essential to optimize the diagnostic evaluation and treatment. Important information on the pattern and extent of the ILD can be obtained by chest HRCT imaging. In general, surgical lung biopsy is not recommended for CTD-associated ILD. All patients with CTD-associated ILD do not require pharmacologic treatment. The decision to treat CTD-associated ILD often depends on 1) whether the patient is clinically impaired by the ILD, 2) whether the ILD is progressive, and 3) what contraindications exist. Differential diagnosis from superimposed pneumonia and drug-induced ILD is quite important. Immunosuppressive therapy is the mainstay of treatment. Recent success of cyclophosphamide in the clinical trials of systemic sclerosis-associated ILD is promising.

Keywords

References

  1. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009;33:882-896. https://doi.org/10.1183/09031936.00152607
  2. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003;29:371-390. https://doi.org/10.1016/S0889-857X(03)00025-5
  3. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008;31:11-20. https://doi.org/10.1183/09031936.00060107
  4. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007;176:691-697. https://doi.org/10.1164/rccm.200702-220OC
  5. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705-711. https://doi.org/10.1164/rccm.200607-912OC
  6. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005;127:2019-2027. https://doi.org/10.1378/chest.127.6.2019
  7. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009;136:23-30. https://doi.org/10.1378/chest.09-2266
  8. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304. https://doi.org/10.1164/ajrccm.165.2.ats01
  9. Fischer A, Brown KK, Frankel SK. Treatment of connective tissue disease-associated interstitial lung disease. Clin Pulm Med 2009;16:74-80. https://doi.org/10.1097/CPM.0b013e31819b5400
  10. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012;380:689-698. https://doi.org/10.1016/S0140-6736(12)61079-4
  11. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010;138:251-256. https://doi.org/10.1378/chest.10-0194
  12. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-1619. https://doi.org/10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O
  13. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666. https://doi.org/10.1056/NEJMoa055120
  14. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026-1034. https://doi.org/10.1164/rccm.200702-326OC
  15. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-954.